Literature DB >> 23984962

Dengue vaccines: recent developments, ongoing challenges and current candidates.

Monica A McArthur1, Marcelo B Sztein, Robert Edelman.   

Abstract

Dengue is among the most prevalent and important arbovirus diseases of humans. To effectively control this rapidly spreading disease, control of the vector mosquito and a safe and efficacious vaccine are critical. Despite considerable efforts, the development of a successful vaccine has remained elusive. Multiple factors have complicated the creation of a successful vaccine, not the least of which are the complex, immune-mediated responses against four antigenically distinct serotypes necessitating a tetravalent vaccine providing long-lasting protective immunity. Despite the multiple impediments, there are currently many promising vaccine candidates in preclinical and clinical development. Here, the recent advances in dengue virus vaccine development are reviewed and the challenges associated with the use of these vaccines as a public health tool are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23984962      PMCID: PMC3773977          DOI: 10.1586/14760584.2013.815412

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  139 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population.

Authors:  Ronald E Blanton; Luciano K Silva; Vanessa G Morato; Antonio R Parrado; Juarez P Dias; Paulo R S Melo; Eliana A G Reis; Katrina A B Goddard; Márcio R T Nunes; Sueli G Rodrigues; Pedro F C Vasconcelos; Jesuina M Castro; Mitermayer G Reis; Maurício L Barreto; M Glória Teixeira
Journal:  Eur J Hum Genet       Date:  2008-02-13       Impact factor: 4.246

3.  Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Authors:  Wellington Sun; Dennis Cunningham; Steven S Wasserman; Judith Perry; J Robert Putnak; Kenneth H Eckels; David W Vaughn; Stephen J Thomas; Niranjan Kanesa-Thasan; Bruce L Innis; Robert Edelman
Journal:  Hum Vaccin       Date:  2009-01-27

4.  T lymphocyte responses to heterologous secondary dengue virus infections.

Authors:  Alan L Rothman
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

Review 5.  Viral vectors as vaccine platforms: deployment in sight.

Authors:  Christine S Rollier; Arturo Reyes-Sandoval; Matthew G Cottingham; Katie Ewer; Adrian V S Hill
Journal:  Curr Opin Immunol       Date:  2011-04-20       Impact factor: 7.486

6.  Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission.

Authors:  S B Halstead; T G Streit; J G Lafontant; R Putvatana; K Russell; W Sun; N Kanesa-Thasan; C G Hayes; D M Watts
Journal:  Am J Trop Med Hyg       Date:  2001-09       Impact factor: 2.345

7.  Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection.

Authors:  Alena Atrasheuskaya; Peter Petzelbauer; Terry M Fredeking; George Ignatyev
Journal:  FEMS Immunol Med Microbiol       Date:  2003-01-21

8.  Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex.

Authors:  Fleur Bossi; Fabio Fischetti; Valentina Pellis; Roberta Bulla; Elisabetta Ferrero; Tom Eirik Mollnes; Domenico Regoli; Francesco Tedesco
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

9.  Japanese Encephalitis Vaccines.

Authors:  Monica A McArthur; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011-09-25

10.  Economic cost of dengue in Puerto Rico.

Authors:  Yara A Halasa; Donald S Shepard; Wu Zeng
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

View more
  25 in total

Review 1.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

2.  Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.

Authors:  Guillaume B E Stewart-Jones; Gwo-Yu Chuang; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Yaroslav Tsybovsky; Li Ou; Baoshan Zhang; Blanca Fernandez-Rodriguez; Valentina Gilardi; Chiara Silacci-Fregni; Martina Beltramello; Ulrich Baxa; Aliaksandr Druz; Wing-Pui Kong; Paul V Thomas; Yongping Yang; Kathryn E Foulds; John-Paul Todd; Hui Wei; Andres M Salazar; Diana G Scorpio; Bridget Carragher; Clinton S Potter; Davide Corti; John R Mascola; Antonio Lanzavecchia; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-12       Impact factor: 11.205

Review 3.  Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? From Data to Understanding through Systems Biology.

Authors:  Thomas Hagan; Bali Pulendran
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-08-01       Impact factor: 10.005

4.  Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies.

Authors:  Jian Hang Lam; Yen Leong Chua; Pei Xuan Lee; Julia María Martínez Gómez; Eng Eong Ooi; Sylvie Alonso
Journal:  JCI Insight       Date:  2017-12-21

Review 5.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

6.  An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.

Authors:  Chung-Tao Tang; Pi-Chun Li; I-Ju Liu; Mei-Ying Liao; Chiung-Yi Chiu; Day-Yu Chao; Han-Chung Wu
Journal:  PLoS Negl Trop Dis       Date:  2015-07-02

Review 7.  Aedes aegypti Control Strategies in Brazil: Incorporation of New Technologies to Overcome the Persistence of Dengue Epidemics.

Authors:  Helena R C Araújo; Danilo O Carvalho; Rafaella S Ioshino; André L Costa-da-Silva; Margareth L Capurro
Journal:  Insects       Date:  2015-06-11       Impact factor: 2.769

8.  The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.

Authors:  Hsin-Wei Chen; Hui-Mei Hu; Szu-Hsien Wu; Chen-Yi Chiang; Yu-Ju Hsiao; Chia-Kai Wu; Chun-Hsiang Hsieh; Han-Hsuan Chung; Pele Chong; Chih-Hsiang Leng; Chien-Hsiung Pan
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

9.  Microbes increase thermal sensitivity in the mosquito Aedes aegypti, with the potential to change disease distributions.

Authors:  Fhallon Ware-Gilmore; Carla M Sgrò; Zhiyong Xi; Heverton L C Dutra; Matthew J Jones; Katriona Shea; Matthew D Hall; Matthew B Thomas; Elizabeth A McGraw
Journal:  PLoS Negl Trop Dis       Date:  2021-07-22

10.  Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.

Authors:  Chung-Tao Tang; Mei-Ying Liao; Chien-Yu Chiu; Wen-Fan Shen; Chiung-Yi Chiu; Ping-Chang Cheng; Gwong-Jen J Chang; Han-Chung Wu
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.